Alza/McNeil Concerta
Executive Summary
"Approvable" letter received May 18 for once-daily OROS formulation of methylphenidate for ADD/ADHD. FDA is not requesting additional clinical data, and the companies continue to plan for a fall launch (1"The Pink Sheet" April 24, p. 7). The NDA was submitted July 21, 1999